作者:Marion Flipo、Julie Charton、Akila Hocine、Sandrine Dassonneville、Benoit Deprez、Rebecca Deprez-Poulain
DOI:10.1021/jm900648x
日期:2009.11.12
display nanomolar activities against metalloproteases, only three hydroxamates have reached the market, among which is the HDAC inhibitor vorinostat. Failures in development are generally attributed to lack of selectivity, toxicity, or poor stability. To help medicinal chemists with respect to plasma stability, we have performed the first and preliminary study on structure−plasma stability for hydroxamates
异羟肟酸酯是用于化学生物学的有价值的工具,也是用于药物化学的有趣线索。尽管许多异羟肟酸酯显示出对金属蛋白酶的纳摩尔活性,但只有三种异羟肟酸酯进入市场,其中包括HDAC抑制剂伏立诺他。开发失败通常归因于缺乏选择性,毒性或稳定性差。为了帮助药用化学家进行血浆稳定性方面的研究,我们对异羟肟酸酯的结构-血浆稳定性进行了首次和初步研究。我们定义一些结构规则,以预测或改善临床前阶段的血浆稳定性。